Merck KGaA’s Pharma Sales Strong For Now But Concerns Remain In UC And MS
Executive Summary
The German major’s healthcare sales saw organic double-digit growth in the second quarter but worries about the viability of its BTK inhibitor approach in multiple sclerosis as well as new competition for cancer drug Bavencio render future prospects less certain.